Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

Overview of attention for article published in Frontiers in oncology, April 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter: 14 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 17 X posts from 14 X users, with an upper bound of 69,752 followers.

RT @FrontOncology: New research: Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advan…

17 Apr 2023

Reply Repost Favourite

New research: Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer: Background Enfortumab vedotin (EV) is an antibody-drug conjugate approved for patients with… https://t.co/zRgrvz

16 Apr 2023

Reply Repost Favourite

RT @koshkin85: With the recent EV/Pembro approval, a timely @FrontOncology manuscript by @Tanjin097 looking at biomarkers of response to en…

09 Apr 2023

Reply Repost Favourite

RT @Tanjin097: This new publication with @koshkin85 in @FrontOncology highlights association of alterations in TP53 and MDM2 with outcomes…

06 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 13 additional X posts.